Advertisement

PharmacoEconomics & Outcomes News

, Volume 817, Issue 1, pp 23–23 | Cite as

Nintedanib preferred option in idiopathic pulmonary fibrosis

Meeting report
  • 45 Downloads

Reference

  1. Soulard S. Cost-Utility of Nintedanib Versus Pirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis: a Belgian Perspective. 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PSY105, 10 Nov 2018. Available from: URL: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/85415?pdfid=56524

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations